睿知中国医院研究地图
候选清单

正在招募胰腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

ClinicalTrials.gov 上登记的一项胰腺癌开放试验。牵头方不是本站收录的医院;本站收录的 7 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 7

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心海军军医大学第一附属医院(长海医院)Changhai Hospital上海医院页面
  2. 研究中心北京协和医院Peking Union Medical College Hospital北京医院页面
  3. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
  4. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  5. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  6. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面
  7. 研究中心浙江省人民医院Zhejiang Provincial People's Hospital杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05859750,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC).

    入选标准第 3 条

  3. Patients have not received prior systemic therapy for locally advanced or metastatic pancreatic cancer; for patients who have received prior induction chemotherapy, concurrent chemoradiotherapy, or adjuvant/neoadjuvant chemotherapy for curative intent, the time between disease progression and last treatment should be at least 6 months.

    入选标准第 4 条

    Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to take effective contraception measures during the study drug administration and within 120 days after the last dose. Male patients with female partners of childbearing potential must agree to take effective contraception measures during the study drug administration and within 120 days after the last dose.

    入选标准第 9 条

    Major surgery other than the diagnosis of pancreatic cancer within 28 days prior to the first dose or major surgery is expected during the study.

    排除标准第 7 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    入选标准第 6 条

  5. Active malignancies within the past 3 years, with the exception of tumors in this study and cured local tumors.

    排除标准第 6 条

    Known medical history of immunodeficiency or positive HIV test.

    排除标准第 15 条

  6. Pregnant or lactating women.

    排除标准第 8 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05859750,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.
  2. Males or females aged ≥ 18 years and ≤ 75 years at the time of signing the ICF.
  3. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC).
  4. Patients have not received prior systemic therapy for locally advanced or metastatic pancreatic cancer; for patients who have received prior induction chemotherapy, concurrent chemoradiotherapy, or adjuvant/neoadjuvant chemotherapy for curative intent, the time between disease progression and last treatment should be at least 6 months.
  5. Patients have at least one measurable tumor lesion per RECIST v1.1; lesions that received radiotherapy are not selected as target lesions, unless the lesion is the only measurable lesion and has unequivocal progression as judged by imaging, it can be considered as a target lesion.
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  7. Expected survival ≥ 3 months.
  8. Patients who have adequate organ function.
  9. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and agree to take effective contraception measures during the study drug administration and within 120 days after the last dose. Male patients with female partners of childbearing potential must agree to take effective contraception measures during the study drug administration and within 120 days after the last dose.

排除标准:Exclusion Criteria:

  1. Histologically or cytologically confirmed other pathological types, such as acinar cell carcinoma, pancreatic neuroendocrine neoplasms or pancreatoblastoma.
  2. Known active or untreated brain metastases, meningeal metastases, spinal cord compression, or leptomeningeal disease.
  3. Patients with known germ line BRAC1/2 mutation.
  4. Presence of clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring frequent drainage (≥ 1/month).
  5. Patients who, in the opinion of the investigator, have symptoms or signs suggestive of clinically unacceptable deterioration of the primary disease at the time of screening.
  6. Active malignancies within the past 3 years, with the exception of tumors in this study and cured local tumors.
  7. Major surgery other than the diagnosis of pancreatic cancer within 28 days prior to the first dose or major surgery is expected during the study.
  8. Pregnant or lactating women.
  9. Patients who received any prior treatments targeting the mechanism of tumor immunity.
  10. Patients with known contraindications to prescribed chemotherapy regimen (see instructions for specific drug).
  11. Patients with known medical history of severe hypersensitivity reactions to other monoclonal antibodies or intravenous gamma globulin.
  12. Active autoimmune disease within 2 years prior to the start of study treatmen.
  13. Known active pulmonary tuberculosis.
  14. Patients with active hepatitis B or active hepatitis C.
  15. Known medical history of immunodeficiency or positive HIV test.
  16. Patients with active infection.
  17. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
  18. Concurrent participation in another clinical study, unless it is an observational, non-interventional clinical study or the follow-up period of an interventional study.
  19. Any condition that, in the opinion of the Investigator, may result in a risk when receiving the study drug, or would interfere with the evaluation of the study drug or the safety of patients, or the interpretation of the study results.

引自 ClinicalTrials.gov, NCT05859750, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05859750,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05859750